Rights and permissions
About this article
Cite this article
Poorer tolerance and higher costs after switch to capecitabine. Pharmacoecon. Outcomes News 646, 10 (2012). https://doi.org/10.1007/BF03272353
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03272353